Related Experiment Video
Updated: Apr 11, 2026
11:15
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
10.7K
Early Detection and Inhibition of Post-Surgical Cancer Recurrence by Synthetic Extracellular Vesicles
Junli Zhang1, Wenjia Chang1, Ruolin Hu1
1School of Pharmaceutical Sciences, Henan Key Laboratory of Nanomedicine for Targeting Diagnosis and Treatment, Zhengzhou University, Zhengzhou, China.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|April 9, 2026
Summary
This study introduces a novel synthetic biomarker system using engineered extracellular vesicles (EVs) for early cancer recurrence detection and treatment after surgery. The method shows promise for improving patient survival by enabling timely intervention.
Area of Science:
- Biomedical Engineering
- Cancer Research
- Molecular Biology
Background:
- Early detection of post-surgical cancer recurrence is critical for improving patient survival.
- Current endogenous biomarkers often lack the sensitivity and specificity needed for effective clinical management.
- Synthetic biomarker approaches offer a promising alternative for enhanced cancer detection.
Purpose of the Study:
- To develop and validate a synthetic biomarker system for early detection and inhibition of post-surgical cancer recurrence.
- To utilize engineered extracellular vesicles (EVs) for improved diagnostic sensitivity and therapeutic efficacy.
- To evaluate the potential of this integrated strategy in a preclinical cancer model.
Main Methods:
- A synthetic extracellular vesicle (EV)-generating system was engineered and embedded at the tumor resection site.
- Tumor cells were reprogrammed to secrete EVs expressing engineered miR-26a (E-miR-26a) for detection or PD-1 for therapeutic effect.
- The E-miR-26a EVs in blood were monitored for early recurrence detection in a mouse model, compared to bioluminescence imaging.
- The therapeutic potential of PD-1-expressing EVs was assessed by their interaction with tumor cells and impact on T cells.
Main Results:
- Monitoring E-miR-26a-expressing EVs in blood enabled more timely detection of post-resection tumor recurrence than traditional bioluminescence imaging.
- The synthetic biomarker strategy successfully detected early-stage tumors across mice with varying tumor burdens.
- Engineered PD-1-expressing EVs demonstrated the ability to bind PD-L1 on tumor cells, enhancing T cell activation and antitumor efficacy.
Conclusions:
- The developed synthetic biomarker system provides an integrated approach for both early detection and treatment of post-surgical cancer recurrence.
- This novel strategy holds significant potential for improving long-term outcomes in cancer patients by enabling prompt intervention.
- Engineered EVs represent a versatile platform for developing advanced cancer diagnostics and therapeutics.
